Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 1:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 67 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Ophthalmologic evaluation Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of Conventional Photorefractive Keratectomy (PRK) in U.S. Army Personnel, Substudy of: Initial Evaluation of Excimer Laser Keratorefractive Surgery in U.S. Army Personnel

NCT00412568
View directory record Official record
Conditions
Myopia
Interventions
Photorefractive Keratectomy (PRK)
Procedure
Lead sponsor
Walter Reed Army Medical Center
Federal
Eligibility
21 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 1, 2008 · Synced Oct 23, 2026, 1:20 AM EDT
Not listed Not applicable Interventional

Prospective Evaluation and Comparison of Bilateral Synergy Implants and Bilateral PanOptix Implants

NCT05186298
View directory record Official record
Conditions
Cataract
Interventions
AcrySof® IQ PanOptix®, Synergy®, Cataract Surgery
Device · Procedure
Lead sponsor
Alterman, Modi, & Wolter Ophthalmic Physicians & Surgeons
Other
Eligibility
22 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
5
States / cities
Panama City, Florida • Poughkeepsie, New York • Kingston, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Oct 23, 2026, 1:20 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Brain Integrity in Survivors of Hodgkin Lymphoma Treated With Thoracic Radiation

NCT01820117
View directory record Official record
Conditions
Hodgkin Lymphoma
Interventions
Neurocognitive Evaluation, Quantitative Brain Imaging, Neurologic Evaluation, Health Questionnaire, Vascular Testing, Cardiopulmonary Exercise Testing, Echocardiography, Pulmonary Function Testing, Serum Biomarkers, Ophthalmology Examination
Other · Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
18 Years and older
Enrollment
416 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 1, 2018 · Synced Oct 23, 2026, 1:20 AM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Smart Soft Contact Lenses for Monitoring Glaucoma

NCT07224542
View directory record Official record
Conditions
Glaucoma
Interventions
Bare Contact Lens, Experimental Smart Contact Lens, Commercially available smart contact lens
Device
Lead sponsor
Indiana University
Other
Eligibility
22 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Bloomington, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 23, 2026, 1:20 AM EDT
Completed Not applicable Interventional

Comparison of LASIK and SBK

NCT00714363
View directory record Official record
Conditions
Myopia
Interventions
LASIK, SBK
Procedure
Lead sponsor
University of Utah
Other
Eligibility
21 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 19, 2010 · Synced Oct 23, 2026, 1:20 AM EDT
Completed Not applicable Interventional Results available

Impact of Pharmacy Clinic on Diabetes Management

NCT03377127
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Pharmacy Managed Diabetes Clinic (PMDC), Standard of Care (SOC)
Behavioral · Other
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years to 75 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
4
States / cities
Berkley, Michigan • Royal Oak, Michigan • Southfield, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced Oct 23, 2026, 1:20 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Prospective Evaluation of Contrast Sensitivity and Disability Glare in Refractive Surgery, a Sub-Study of: Initial Evaluation of Excimer Laser Keratorefractive Surgery in U.S. Army Personnel (WU # 2335-99)

NCT00413868
View directory record Official record
Conditions
Myopia
Interventions
LASIK, PRK, Small target contrast sensitivity and disability glare
Procedure · Behavioral
Lead sponsor
Walter Reed Army Medical Center
Federal
Eligibility
21 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 1, 2008 · Synced Oct 23, 2026, 1:20 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution to Treat Non-Infectious Anterior Segment Uveitis

NCT01505088
View directory record Official record
Conditions
Anterior Uveitis
Interventions
40 mg/mL Dexamethasone phosphate ophthalmic solution, Prednisolone Acetate (1%) Eyedrops, 100 mM sodium citrate buffer solution, Placebo Eyedrops
Drug
Lead sponsor
Eyegate Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 85 Years
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
39
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2013 · Synced Oct 23, 2026, 1:20 AM EDT
Completed Phase 4 Interventional Results available

Ophthalmologic Safety Study of Pramipexole Immediate Release (IR) Versus Ropinirole in Early Parkinson's Disease (PD) Patients

NCT00144300
View directory record Official record
Conditions
Parkinson Disease
Interventions
Mirapex, Requip
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
30 Years and older
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
21
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Fountain Valley, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2014 · Synced Oct 23, 2026, 1:20 AM EDT
Completed Not applicable Interventional

EFFECTIVENESS AND SAFETY ASSESSMENT OF THE VISTA VITRECTOMY PROBE

NCT07140692
View directory record Official record
Conditions
Vitreous Floaters, Vitreous Opacities
Interventions
Vitrectomy
Device
Lead sponsor
The Eye Centers of Racine and Kenosha
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Kenosha, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 25, 2025 · Synced Oct 23, 2026, 1:20 AM EDT
Recruiting No phase listed Observational

Real-World Assessment of VEVYE® for Short-Term Symptom and Sign Improvement of Dry Eye Disease in a Neuro-Ophthalmology Clinic: A 6-Month Prospective Observational Study

NCT07566975
View directory record Official record
Conditions
Dry Eye
Interventions
Cyclosporine ophthalmic solution 0.1%
Other
Lead sponsor
Neuro-Ophthalmology of Texas
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 23, 2026, 1:20 AM EDT
Enrolling by invitation Phase 3 Interventional

A Phase 3 Study Evaluating the Safety and Efficacy of TRIESENCE® (Injectable Suspension) for the Treatment of Ocular Inflammation and Pain After Ophthalmic Surgery

NCT07832552
View directory record Official record
Conditions
Postoperative Ocular Inflammation, Postoperative Ocular Pain
Interventions
Sham (No Treatment), TRIESENCE (triamcinolone acetonide injectable suspension)
Procedure · Drug
Lead sponsor
Harrow Inc
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 23, 2026, 1:20 AM EDT
Completed No phase listed Observational

Evaluation of Visual Acuity of the Envista One-piece Acrylic Toric IOL MX60ET

NCT05739656
View directory record Official record
Conditions
Astigmatism
Interventions
CATARACT SURGERY
Procedure
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 22, 2023 · Synced Oct 23, 2026, 1:20 AM EDT
Terminated No phase listed Observational

Evaluation of Ocular Lens Proteins in Cataract From Individuals With Down Syndrome

NCT03778528
View directory record Official record
Conditions
Cataract, Down Syndrome
Interventions
cataract surgery
Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
1 Month to 18 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Oct 23, 2026, 1:20 AM EDT
Completed Not applicable Interventional Results available

Clinical Investigation of the WaveLight® EX500 Excimer Laser

NCT04805593
View directory record Official record
Conditions
Hyperopia, Hyperopic Astigmatism
Interventions
WaveLight EX500 excimer laser system, LASIK
Device · Procedure
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
5
States / cities
Overland Park, Kansas • Kansas City, Missouri • Greensboro, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Oct 23, 2026, 1:20 AM EDT
Recruiting Phase 4 Interventional

Safety and Efficacy of iDose® TR With Cataract Surgery vs. Cataract Surgery Alone

NCT06848946
View directory record Official record
Conditions
Glaucoma, Open-angle, Ocular Hypertension (OHT), Phacoemulsification Cataract Surgery
Interventions
iDose TR (travoprost intracameral implant) 75 µg in conjunction with cataract surgery, Sham procedure in conjunction with cataract surgery
Combination Product · Procedure
Lead sponsor
Glaukos Corporation
Industry
Eligibility
45 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Kenosha, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 23, 2026, 1:20 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)

NCT05769153
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration (nAMD)
Interventions
AR-14034 SR implant lower dose, AR-14034 SR implant higher dose, AR-14034 SR implant, Aflibercept Injection, Sham procedure
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
50 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
42
States / cities
Dothan, Alabama • Gilbert, Arizona • Phoenix, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 23, 2026, 1:20 AM EDT
Terminated Phase 3 Interventional Results available

Study to Evaluate Eye Function in Patients Taking Linezolid for Six Weeks or Greater

NCT00359632
View directory record Official record
Conditions
Optic Nerve Diseases
Interventions
Zyvox - linezolid, Matched control
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
7
States / cities
Jonesboro, Arkansas • West Palm Beach, Florida • New Orleans, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2015 · Synced Oct 23, 2026, 1:20 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis

NCT03952637
View directory record Official record
Conditions
Lysosomal Diseases, Gangliosidosis, GM1
Interventions
AAV9-GLB1, Abdominal ultrasound, Rituximab, Sirolimus, Methylprednisolone, Prednisone, Audiology assessment with ABR, Bone density scan (DEXA), Electrocardiogram (EKG), Echocardiogram, Electroencephalogram (EEG) awake and extended overnight, Laboratory tests, Lumbar puncture, Brain MRI/MRS/fMRI, Neurocognitive testing, Neurology exam, PICC or other Central line placement, Skeletal survey, Skin biopsy, Speech and modified barium swallow study, Ophthalmology exam
Biological · Procedure · Drug + 3 more
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
6 Months to 12 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 23, 2026, 1:20 AM EDT
Completed No phase listed Observational Results available

Chart Review of XEN 45 Gel Stent: Long Term Performance and Safety Assessment (XEN LT)

NCT03868254
View directory record Official record
Conditions
Glaucoma
Interventions
XEN Group, Phacoemulsification
Device · Procedure
Lead sponsor
Allergan
Industry
Eligibility
Not listed
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Oct 23, 2026, 1:20 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Atlas of Retinal Imaging in Alzheimer's Study

NCT03862222
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Mild Dementia, Aging, Cognitive Change
Interventions
Retinal Imaging, Pupillometry, Contrast Sensitivity, Neuropsychological Evaluation, APOE genotyping, blood draw, Gait Assessment, Actigraphy
Other · Diagnostic Test · Genetic
Lead sponsor
University of Rhode Island
Other
Eligibility
55 Years to 80 Years
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
4
States / cities
Clearwater, Florida • St. Petersburg, Florida • Kingston, Rhode Island + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 23, 2026, 1:20 AM EDT
Completed Not applicable Interventional

Technology-based Eye Care Services (TECS) Compare

NCT02558712
View directory record Official record
Conditions
Cataract, Macular Degeneration, Glaucoma
Interventions
Technology-based Eye Care Services (TECS) Protocol
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 13, 2018 · Synced Oct 23, 2026, 1:20 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Non-Infectious Anterior Uveitis

NCT02517619
View directory record Official record
Conditions
Anterior Uveitis
Interventions
Dexamethasone Phosphate Ophthalmic Solution, Prednisolone Acetate Ophthalmic (1%)
Drug
Lead sponsor
Eyegate Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 85 Years
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Oct 23, 2026, 1:20 AM EDT
Completed Not applicable Interventional Results available

Geriatric-assessment Interventions to Address Functional Deficits in Older Adults w Multiple Myeloma

NCT04999085
View directory record Official record
Conditions
Multiple Myeloma, Myeloma, Disability Physical, Disabilities Multiple
Interventions
Supportive care interventions
Other
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
60 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 28, 2025 · Synced Oct 23, 2026, 1:20 AM EDT